Cannabis Habit More Likely with Genetic Predisposition to Schizophrenia
the Psychiatry Advisor take:
Previous research has establish an association between cannabis use and schizophrenia, but it is unknown whether cannabis use increases psychosis risk, or whether the same genes that predispose individuals to psychosis predispose individuals to cannabis use.
To better understand this relationship, Robert Power, of the MRC Social, Genetic & Developmental Psychiatry Centre, in the Institute of Psychiatry at King's College London, and colleagues analyzed data from a sample 2,082 healthy individuals, about half of whom had used cannabis.
The researchers assigned participants to a genetic risk profile based on the number of genes associated with schizophrenia that they carried, and then looked at their likelihood of cannabis use.
Participants whose genetic risk profile predisposed them to schizophrenia were more likely to use cannabis (P=2.6 × 10−4), and to use it more (P=3.0 × 10−3), than those who did not carry schizophrenia risk genes, data indicated.
"[T]hese findings suggest that part of the association between schizophrenia and cannabis is due to a shared genetic aetiology. This form of gene–environment correlation is an important consideration when calculating the impact of environmental risk factors, including cannabis use," the researchers reported in Molecular Psychology.
The study findings are particularly important in the context of the debate about legalizing marijuana.
"Certain environmental risks, such as cannabis use, may be more likely given an individual's innate behavior and personality, itself influenced by their genetic make-up. This is an important finding to consider when calculating the economic and health impact of cannabis," they wrote.
Individuals who carry schizophrenia risk genes were more likely to use cannabis and to use it more, than those without the genes.
Cannabis Habit More Likely with Schizophrenia Gene
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Should Physicians Treat Family and Friends? Three Experts Weigh In
- Transference in the Age of #MeToo: What Counts as Harassment From a Patient?
- Dialectical Behavior Therapy Effective in Reducing Suicide Attempts, Self-Harm in Adolescents
- Influence of Psychostimulants on BMI and Height in Youth With ADHD
- Medication Adherence Predictors in Patients With Severe Psychiatric Disorders
- Court-Mandated Substance Abuse Treatment: Exploring the Ethics and Efficacy
- ADHD Treatments
- Esketamine Nasal Spray: A New Treatment Possibility for Treatment-Resistant Depression
- Pharmacogenetics in Psychiatry: Promising Developments and Potential Pitfalls
- Substance Abuse and Primary Psychosis: A Closer Look
- Functional Restoration for Chronic Pain and Depression in the Elderly: Pharmacotherapy and Beyond
- Efficacy of Long-Acting Injectable Antipsychotics vs Oral Antipsychotics
- Older Age Associated With Worse Major Depressive Disorder Outcomes
- Preoperative Psychiatric Diagnoses Not Associated With Bariatric Surgery Outcomes
- Medical Clearance of Psych Patients in the ED: Consensus Recommendations